Glycopyrronium does not affect QT interval in healthy subjects: A randomized, three-period, cross-over, placebo- and positive-controlled study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 9, 2014, Pages 739-745

  Drollmann, Anton ^a   Sechaud, Romain ^a   Pal, Parasar ^b   Hara, Hisanori ^a   Uziel Fusi, Susan ^a   Winkle, Peter ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Healthcare Private Limited   (India)

^c Advanced Clinical Research Institute   (United States)

Author keywords

Cardiac safety; Glycopyrronium; Moxifloxacin; QTcF; Thorough QT study

Indexed keywords

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ARRHYTHMIAS, CARDIAC; CROSS-OVER STUDIES; FEMALE; GLYCOPYRROLATE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84905864587     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202096     Document Type: Article

References (17)

1. Global Initiative for Chronic Obstructive Lung Disease. (GOLD 2013). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2013. www goldcopd org.
2. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. PLoS ONE. 2013; 8: e63285. CrossRef PubMed
3. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellón-Cano JM; CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012; 7: 679-686. PubMed
4. Slenter RHJ, Sprooten RTM, Kotz D, Wesseling G, Wouters EFM, Rohde GG. Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration. 2013; 85: 15-26. CrossRef PubMed
5. Singh S, Loke YK, Furberg C. D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA. 2008; 300: 1439-1450. CrossRef PubMed
6. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006; 61: 854-862. CrossRef PubMed (Pubitemid 44570305)
7. Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assessment. 2013; 2: 11-16.
8. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012; 343: 520-528. CrossRef PubMed
9. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7: 503-513. CrossRef PubMed
10. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011; 12: 156. CrossRef PubMed
11. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VKT, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Respir J. 2012; 40: 1106-1114. CrossRef PubMed
12. Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Güçlü SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010; 23: 438-444. CrossRef PubMed
13. International Conference on Harmonization (ICH). Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. http://www.fda.gov/ RegulatoryInformation/Guidances/ucm 129335.htm
14. Démolis JL, Kubitza D, Tennezé L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000; 68: 658-666. CrossRef PubMed (Pubitemid 32059992)
15. Sechaud R, Renard D, Zhang-Auberson L, Motte SL, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012; 50: 118-128. CrossRef PubMed
16. Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat. 2010; 20: 497-507. CrossRef PubMed
17. Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D. Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2010; 21: 905-913. PubMed